Weekly Funding Opportunities

[Med Research]

NIA Program Project Applications (P01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-19-314.html>
The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission. Each application submitted to this FOA must include at least three related research projects that share a common central theme, focus, and/overall objective and an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award.
Standard dates apply. Expires May 26, 2022. Med-RA deadline to receive draft documents for September 25, 2019 deadline: September 12, 2019.

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-19-325.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Due September 30, 2019; February 11, 2020; September 30, 2020; February 11, 2021; September 20, 2021; and February 11, 2022. Med-RA deadline to receive draft documents for September 2019 deadline: September 17, 2019.

Palliative Care in Home and Community Settings (R21 / R01 Clinical Trial Optional)
R21<https://grants.nih.gov/grants/guide/pa-files/par-19-320.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-19-321.html>
The purpose of these funding opportunities is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in these FOAs refers to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.
Standard dates apply. Expires September 8, 2022. Due October 5 and October 16. Med-RA deadline to receive draft documents for October R01 deadline: September 24 and R21 deadline: October 3, 2019.

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-19-309.html>
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.
Standard dates apply. Expires September 08, 2022. Med-RA deadline to receive draft documents for October 16, 2019 deadline: October 3, 2019.

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-19-310.html>
This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.
Standard dates apply. Expires January 08, 2022. Med-RA deadline to receive draft documents for October 16, 2019 deadline: October 3, 2019.

Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-035.html>
This FOA will use the NIH Resource-Related Research Project (R24) mechanism to facilitate the development of research networks to advance research on the basic biology of aging in health disparities. The infrastructure-building aspect of this FOA will be to establish collaborations for subsequent research on the biology of aging underlying health disparities. The intention is to provide a platform for discovery and pilot projects to establish feasibility of novel approaches to be used by these collaborations. For this FOA, the key human population feature of health disparities is accelerated aging.
Due October 18, 2019 and October 19, 2020. Med-RA deadline to receive draft documents for October 2019 deadline: October 7, 2019.

Implementation Research on Hypertension Control to Prevent Dementia and Cognitive Decline (R61 / R33 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-028.html>
This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials on dissemination and implementation of practical approaches to hypertension treatment and control strategies among older adults with multimorbidity in order to prevent sequelae, including mild cognitive impairment and dementia. The research will: (1) be designed to address practical hypertension treatment questions faced by older adults with multimorbidity and their clinicians, (2) include broad and diverse populations, and (3) be conducted in real-world settings. These trials are intended to produce results that can be directly adopted by healthcare systems for rapid translation. This FOA will support pilot research to test the feasibility of implementing care interventions (R61 phase) that, if successful, can transition to an R33 phase for implementation of large pragmatic trials.
Due October 22, 2019. Med-RA deadline to receive draft documents: October 9, 2019.

Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76)
K76 (Clinical Trial Required)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-011.html>
K76 (Independent Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/rfa-ag-20-010.html>
These Funding Opportunity Announcements (FOAs) invite early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for these awards to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. NIA is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through these awards, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for these awards must have received competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.
Due October 22, 2019. Med-RA deadline to receive draft documents: October 9, 2019.

Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Alzheimer's Disease (R21 / R01 Clinical Trial Not Allowed)
R21<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-041.html>
This Funding Opportunity Announcement (FOA) invites early stage innovative and exploratory research focusing on understanding the regulation of brain regional and cell type-specific protein dynamics in Alzheimer's disease (AD). In particular, this FOA seeks applications proposing to develop novel proteomic platforms and animal models to further understanding of the alteration of a single-cell neuronal cell proteome in the central nervous system during the course of aging and AD.
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-042.html>
This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in Alzheimer's disease (AD). Specifically, this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD.
Due October 23, 2019. Med-RA deadline to receive draft documents: October 10, 2019.

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-19-011.html>
The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG's Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins. The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base.
Due October 28, 2019. Med-RA deadline to receive draft documents: October 15, 2019.

Microbiome and Aging: Impact on Health and Disease (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-20-030.html>
This Funding Opportunity Announcement (FOA) invites projects focused on defining the factors that influence microbiome composition and functional characteristics during aging, understanding how the aging microbiome relates to the causes and pathophysiology of age-related chronic diseases, and development and testing of targeted interventions through diet, drugs, or live organisms. This FOA will accept basic mechanistic, preclinical studies in animal models and human studies leveraging existing human longitudinal cohorts.
Due October 30, 2019. Med-RA deadline to receive draft documents: October 17, 2019.

NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-19-319.html>
The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.
Due October 31, 2019; March 3, 2020; June 30, 2020; October 27, 2020; March 2, 2021; June 29, 2021; October 26, 2021; March 1, 2022; and June 28, 2022. Med-RA deadline to receive draft documents for October 31, 2019 deadline: October 21, 2019.

Preclinical Screening for Natural Product Drug Interactions (Clinical Trial Not Allowed, R21)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-20-001.html>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that seek to identify natural products with the potential to inhibit or induce Phase I and Phase II drug metabolizing enzymes and drug transporters, thereby possibly contributing to pharmacokinetic interactions with other medications. These in vitro studies may include screening libraries of complex extracts and/or purified natural products in suitable medium to high throughput assays to identify potential interactions. They may also include isolation and identification of novel, or not commercially available, natural products within complex mixtures that exhibit pharmacokinetic interactions. This FOA is part of a larger investment from NCCIH that includes a U54 Center of Excellence for Natural Product Drug Interaction Research. It is expected that data generated in projects supported under this FOA will be uploaded and made publicly available through the data repository maintained by the U54 Center.
Due November 1, 2019. Med-RA deadline to receive draft documents: October 21, 2019.

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-011.html>
This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.
The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.
Due November 1, 2019; December 2, 2019; January 2, 2020; February 3, 2020; March 2, 2020; April 1, 2020; May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021; June 1, 2021; July 1, 2021; August 2, 2021; September 1, 2021; October 1, 2021; November 1, 2021; December 1, 2021; January 3, 2022; February 1, 2022; March 1, 2022; April 1, 2022; May 2, 2022; June 1, 2022; July 1, 2022; August 1, 2022; September 1, 2022; and October 3, 2022. Med-RA deadline to receive draft documents for November 1, 2019 deadline: October 21, 2019.

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-023.html>
This Funding Opportunity Announcement (FOA) invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced microglia and cerebral organoids generated from human derived induced pluripotent stem cell (iPSC) lines.
Due November 12, 2019. Med-RA deadline to receive draft documents: October 29, 2019.

Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R21 / R01 - Clinical Trials Not Allowed)
R21<https://grants.nih.gov/grants/guide/rfa-files/rfa-da-20-007.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-006.html>
The purpose of these funding opportunity announcements is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.
Due November 14, 2019. Med-RA deadline to receive draft documents: October 31, 2019.

Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 / R01 - Clinical Trials Not Allowed)
R21<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-009.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/rfa-da-20-008.html>
The purpose of these funding opportunity announcements is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology.
Due November 14, 2019. Med-RA deadline to receive draft documents: October 31, 2019.

NSF: Ecology and Evolution of Infectious Diseases (EEID)<https://www.nsf.gov/pubs/2019/nsf19592/nsf19592.htm>
The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.
Due November 20, 2019. Med-RA deadline to receive draft documents: November 6, 2019.

To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20190802/5aa3600b/attachment.html>